Outcomes for patients by randomized allocation
| . | LDAC . | Clo . | HR/OR (95% CI) . | P value . |
|---|---|---|---|---|
| CR | 12% | 22% | 0.47 (0.28-0.79) | .005 |
| CRi | 8% | 16% | ||
| ORR (CR + CRi) | 19% | 38% | 0.41 (0.26-0.62) | <.0001 |
| Resistant disease | 67% | 44% | 0.39 (0.27-0.58) | <.0001 |
| Induction death | 13% | 18% | 1.42 (0.83-2.44) | .2 |
| 30-d mortality | 13% | 18% | ||
| 60-d mortality | 26% | 32% | ||
| 2-y survival | 12% | 13% | 0.96 (0.78-1.19) | .7 |
| 2-y RFS | 8% | 20% | 0.76 (0.49-1.19) | .2 |
| 2-y survival from CR | 44% | 26% | 1.19 (0.74-1.91) | .5 |
| 2-y survival from relapse | 8% | 0% | 1.91 (1.10-3.31) | .02 |
| 2-y survival for non-CR | 4% | 3% | 1.37 (1.06-1.76) | .02 |
| . | LDAC . | Clo . | HR/OR (95% CI) . | P value . |
|---|---|---|---|---|
| CR | 12% | 22% | 0.47 (0.28-0.79) | .005 |
| CRi | 8% | 16% | ||
| ORR (CR + CRi) | 19% | 38% | 0.41 (0.26-0.62) | <.0001 |
| Resistant disease | 67% | 44% | 0.39 (0.27-0.58) | <.0001 |
| Induction death | 13% | 18% | 1.42 (0.83-2.44) | .2 |
| 30-d mortality | 13% | 18% | ||
| 60-d mortality | 26% | 32% | ||
| 2-y survival | 12% | 13% | 0.96 (0.78-1.19) | .7 |
| 2-y RFS | 8% | 20% | 0.76 (0.49-1.19) | .2 |
| 2-y survival from CR | 44% | 26% | 1.19 (0.74-1.91) | .5 |
| 2-y survival from relapse | 8% | 0% | 1.91 (1.10-3.31) | .02 |
| 2-y survival for non-CR | 4% | 3% | 1.37 (1.06-1.76) | .02 |
CI, confidence interval; Clo, clofarabine; ORR, overall remission rate; RFS, relapse-free survival.